Advances in Mass Spectrometry Enabled Drug Discovery

October 29, 2024
Tuesday
8:20 AM to 5:35 PM

475 Via Ortega
Stanford, California 94305
Mackenzie Room, Jen-Hsun Huang Engineering Center

On October 29, 2024, the inaugural Stanford Cancer Institute Advances in Mass Spectrometry Enabled Drug Discovery symposium successfully convened leading experts from academia and industry. The event focused on the transformative role of mass spectrometry in drug development, exploring current challenges, opportunities, and recent advancements in the field. Photos of the event can be viewed here.

This field has revolutionized ligand and target discovery by enabling the detection of interactions proteome-wide. Chemoproteomic techniques targeting reactive residues have grown and expanded the scope of covalent ligand discovery. Mass spectrometry instrumentation continues to improve, deepening proteomic coverage, accuracy, and sensitivity while becoming more accessible.

Agenda, Speakers, Moderators

Agenda
Speakers
Moderators

7:30 - 8:20 am
Registration Open & Continental Breakfast

8:20 - 8:30 am
Welcome
Nathanael Gray, PhD
Stanford University

Steven Artandi, MD, PhD
Stanford University

8:30 - 10:10 am
Session I: Using mass spectrometry platforms for ligand discovery

Haopeng Xiao, PhD [Moderator]
Stanford University

Matt Patricelli, PhD
Vividion Therapeutics
Lessons and learnings from 8 years of chemoproteomics centered drug discovery

Sherry Niessen, PhD
Belharra Therapeutics
Employing a chemoproteomic platform to target key disease transcription factors

Katelyn Cassidy, PhD
C4 Therapeutics
Chemoproteomics mediated mining for novel covalent ligands to conventionally undruggable targets

Paola Castaldi, PhD
Matchpoint Therapeutics
Targeted covalent drug discovery

10:10- 10:30 am
Session 1 Panel Discussion

10:30 -10:40 am
Break

10:40 - 11:30 am
Session 2: Expanding covalency in drug design

Tyzoon Nomanbhoy, PhD [Moderator]
Vicinitas Therapeutics

Kevan Shokat, PhD
University California, San Francisco
Overcoming the undruggable nature of the most common human oncogene, K-Ras

Jack Taunton, PhD
University California, San Francisco
Mutant-selective AKT inhibitors driven by lysine targeting and neo-zinc chelation

11:30 - 11:45 am
Session 2 Panel Discussion

11:45 - 12:45 pm
Lunch

12:45 - 1:35 pm
Session 3: MS technology & discovery proteomics

Ruth Huttenhain, PhD [Moderator]
Stanford University

Brian Searle, PhD
Ohio State University
Proteomics measurements at scale

Peter Jackson, PhD
Stanford University
Decoding combination therapies to improve Insulin secretion with phosphoproteomics and kinase inhibitor screening

1:35- 1:50 pm
Session 3 Panel Discussion

1:50 - 2:35 pm
Trainee Lightning Talks

Casey Powers, PhD [Moderator]
Stanford University

Brendan Dwyer, PhD
Stanford University
Proteomic approaches for developing chemical tools to rationally reprogram transcription in cancer

Shizhong Dai, PhD
Stanford University
Functionalizing living proteomes with the next generation proximity labeling enzyme, FlexID

Steven Shuken, PhD
Harvard University
High-throughput targeted quantification of drug-protein interaction and PTM sites with the GoDig mass spectrometry platform

2:35 - 2:45 pm
Break

2:45 - 4:00 pm
Session 4: Advancing activity-based protein profiling

Matthew Bogyo, PhD [Moderator]
Stanford University

Ben Cravatt, PhD
Scripps Research Institute
Activity-based protein profiling – protein and ligand discovery on a global scale

Keriann Backus, PhD
University of California, Los Angeles
Photosensitizer-based subcellular lipid and protein interactomics

Ekaterina Vinogradova, PhD
Rockefeller University
Chemical proteomic approaches to study immune cell dysfunction

4:00 - 4:20 pm
Session 4 Panel Discussion

4:20 - 4:30 pm
Break

4:30- 5:20 pm
Session 5: Developing proximity-based therapeutics

Uche Medoh, PhD [Moderator]
Arc Institute

Katherine Donovan, PhD
Dana Farber Cancer Institute
Unveiling the hidden interactome of CRBN molecular glues with chemoproteomics

Pete Wildes, PhD
Revolution Medicines
Using a neomorphic protein interface to catalyze covalent inhibition of aspartic acid in RAS G12D

5:20 - 5:35 pm
Session 5 Panel Discussion

5:35 - 5:45 PM
Ending remarks

Matt Patricelli, PhD
Vividion Therapeutics

Nathanael Gray, PhD
Stanford University

5:45 - 6:30 pm
Reception

Steven Artandi, MD, PhD

Director
Stanford Cancer Institute

Keriann Backus, PhD

Assistant Professor, Biological Chemistry, Chemistry and Biochemistry
PI, The Backus Lab
UCLA

Katelyn Cassidy, PhD

Senior Proteomics Scientist
Team Leader
C4 Therapeutics

Paola Castaldi, PhD

Senior Vice President, Head of Platform and Chemical Biology
Matchpoint Therapeutics

Ben Cravatt, PhD

Professor and Gilula Chair, Chemical Biology
PI, The Cravatt Lab
Scripps Research Institute

Katherine Donovan, PhD

Lead Scientist/Managing Director
Fischer Labs
Dana Farber Cancer Institute

Peter Jackson, PhD

Professor of Microbiology and Immunology, Baxter Labs, and of Pathology
Faculty Director, Stanford Cancer Center Proteomics
Faculty Director, Stanford University Mass Spectrometry
PI, The Jackson Lab
Stanford University

Sherry Niessen, PhD

Vice President, Head of Platform & Proteomics
Belharra Therapeutics

Matt Patricelli, PhD

Chief Scientific Officer
Vividion Therapeutics

Brian Searle, PhD

Assistant Professor, Department of Biomedical Informatics
Ohio State University Medical Center.
Courtesy Assistant Professor, Department of Chemistry and Biochemistry, Ohio State University

Kevan Shokat, PhD

Professor, Department of Cellular and Molelcular Pharmacology
PI, The Shokat Lab
UCSF

Jack Taunton, PhD

Professor, Cellular Molecular Pharmacology
PI, The Taunton Lab
UCSF

Ekaterina Vinogradova, PhD

Assistant Professor
Head of Laboratory of Chemical Immunology and Proteomics
PI, The Vinogradova Lab
Rockefeller University

Pete Wildes, PhD

Vice President, Cancer Biology
Revolution Medicine

Matthew Bogyo, PhD

Professor
Stanford University

Ruth Huttenhain, PhD

Assistant Professor
Stanford University

Uche Medoh, PhD

Science Fellow
Arc Institute

Casey Powers, PhD

Staff Scientist for Education & Proteomics
Stanford SUMS

Tyzoon Nomanbhoy, PhD

Vice President of Chemical Biology
Vicinitas Therapeutics

Haopeng Xiao, PhD

Assistant Professor of Biochemistry
Stanford University

Registration

Thank you for your interest in the Advances in Mass Spectrometry Enabled Drug Discovery symposium on October 29, 2024. We are currently at capacity for the event, and registration is closed.

Location and Parking

Jen-Hsun Huang Engineering Center building

Mackenzie Room, 3rd Floor
Jen-Hsun Huang Engineering Center
475 Via Ortega, Stanford CA 94305
Google Maps

Parking

There are two parking garages near the Huang Engineering Center. If you are a visitor to campus, you can use ParkMobile in visitor parking areas. The hourly rate is $4.46 and the daily rate is $35.68. Click here for more information on visitor parking.

Parking Structure 2
285 Panama St, Stanford CA 94305
Visitor parking is available on the ground floor

Roble Field Garage
369 Santa Teresa St, Stanford CA 94305
Underground garage located between Santa Teresa and Panama St

Organizers

Nathanael Gray, PhD

Krishnan-Shah Family Professor, Chemical and Systems Biology
Co-director, Cancer Drug Discovery
Co-leader, Cancer Therapeutics Research Program
Program Leader, Small Molecule Drug Discovery for the Innovative Medicines Accelerator
PI, The Gray Lab
Stanford University